CERUS CORP (CERS) Stock Fundamental Analysis

NASDAQ:CERS • US1570851014

2.38 USD
0 (0%)
At close: Feb 24, 2026
2.41 USD
+0.03 (+1.26%)
After Hours: 2/24/2026, 8:14:24 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

CERS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. CERS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CERS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • CERS had negative earnings in the past year.
  • In the past year CERS had a positive cash flow from operations.
  • In the past 5 years CERS always reported negative net income.
  • In the past 5 years CERS reported 4 times negative operating cash flow.
CERS Yearly Net Income VS EBIT VS OCF VS FCFCERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -7.42%, CERS is in the better half of the industry, outperforming 64.86% of the companies in the same industry.
  • CERS has a Return On Equity (-25.97%) which is in line with its industry peers.
Industry RankSector Rank
ROA -7.42%
ROE -25.97%
ROIC N/A
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
CERS Yearly ROA, ROE, ROICCERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • CERS has a better Gross Margin (60.50%) than 63.24% of its industry peers.
  • In the last couple of years the Gross Margin of CERS has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for CERS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
CERS Yearly Profit, Operating, Gross MarginsCERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CERS has more shares outstanding
  • The number of shares outstanding for CERS has been increased compared to 5 years ago.
  • The debt/assets ratio for CERS is higher compared to a year ago.
CERS Yearly Shares OutstandingCERS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CERS Yearly Total Debt VS Total AssetsCERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • CERS has an Altman-Z score of -3.89. This is a bad value and indicates that CERS is not financially healthy and even has some risk of bankruptcy.
  • CERS has a Altman-Z score of -3.89. This is in the lower half of the industry: CERS underperforms 65.95% of its industry peers.
  • The Debt to FCF ratio of CERS is 505.38, which is on the high side as it means it would take CERS, 505.38 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of CERS (505.38) is better than 65.95% of its industry peers.
  • A Debt/Equity ratio of 0.79 indicates that CERS is somewhat dependend on debt financing.
  • CERS's Debt to Equity ratio of 0.79 is on the low side compared to the rest of the industry. CERS is outperformed by 71.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF 505.38
Altman-Z -3.89
ROIC/WACCN/A
WACC10.42%
CERS Yearly LT Debt VS Equity VS FCFCERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • CERS has a Current Ratio of 1.89. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.89, CERS is not doing good in the industry: 65.41% of the companies in the same industry are doing better.
  • CERS has a Quick Ratio of 1.29. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
  • CERS's Quick ratio of 1.29 is on the low side compared to the rest of the industry. CERS is outperformed by 64.86% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.29
CERS Yearly Current Assets VS Current LiabilitesCERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 27.27% over the past year.
  • CERS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.18%.
  • CERS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.50% yearly.
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)14.18%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%14.52%

3.2 Future

  • Based on estimates for the next years, CERS will show a very strong growth in Earnings Per Share. The EPS will grow by 27.91% on average per year.
  • Based on estimates for the next years, CERS will show a quite strong growth in Revenue. The Revenue will grow by 14.35% on average per year.
EPS Next Y25.82%
EPS Next 2Y27.64%
EPS Next 3Y27.91%
EPS Next 5YN/A
Revenue Next Year24.59%
Revenue Next 2Y16.8%
Revenue Next 3Y14.35%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CERS Yearly Revenue VS EstimatesCERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
CERS Yearly EPS VS EstimatesCERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CERS. In the last year negative earnings were reported.
  • Also next year CERS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERS Price Earnings VS Forward Price EarningsCERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, CERS is valued a bit cheaper than the industry average as 65.95% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 2721.28
EV/EBITDA N/A
CERS Per share dataCERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CERS's earnings are expected to grow with 27.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.64%
EPS Next 3Y27.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CERS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CERUS CORP

NASDAQ:CERS (2/24/2026, 8:14:24 PM)

After market: 2.41 +0.03 (+1.26%)

2.38

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06
Earnings (Next)03-02
Inst Owners70.5%
Inst Owner Change2.06%
Ins Owners2.94%
Ins Owner Change-0.24%
Market Cap457.17M
Revenue(TTM)225.97M
Net Income(TTM)-15.96M
Analysts80
Price Target4.76 (100%)
Short Float %3.62%
Short Ratio4.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)46.52%
Min EPS beat(2)-6.95%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)28.92%
Min EPS beat(4)-6.95%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)28.86%
EPS beat(12)7
Avg EPS beat(12)15.59%
EPS beat(16)11
Avg EPS beat(16)17.8%
Revenue beat(2)0
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-5.44%
Max Revenue beat(2)-5.03%
Revenue beat(4)1
Avg Revenue beat(4)-6.17%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-5.95%
Revenue beat(12)2
Avg Revenue beat(12)-6.05%
Revenue beat(16)6
Avg Revenue beat(16)-2.43%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)62.5%
EPS NY rev (1m)0%
EPS NY rev (3m)31.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.02
P/FCF 2721.28
P/OCF 128.2
P/B 7.44
P/tB 7.6
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)0
FCFY0.04%
OCF(TTM)0.02
OCFY0.78%
SpS1.18
BVpS0.32
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.42%
ROE -25.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.5%
FCFM 0.07%
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
F-Score5
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF 505.38
Debt/EBITDA N/A
Cap/Depr 248.94%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.29
Altman-Z -3.89
F-Score5
WACC10.42%
ROIC/WACCN/A
Cap/Depr(3y)132.31%
Cap/Depr(5y)95.58%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y25.82%
EPS Next 2Y27.64%
EPS Next 3Y27.91%
EPS Next 5YN/A
Revenue 1Y (TTM)14.18%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%14.52%
Revenue Next Year24.59%
Revenue Next 2Y16.8%
Revenue Next 3Y14.35%
Revenue Next 5YN/A
EBIT growth 1Y19.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year176.36%
EBIT Next 3Y54.48%
EBIT Next 5YN/A
FCF growth 1Y100.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y111.99%
OCF growth 3YN/A
OCF growth 5YN/A

CERUS CORP / CERS FAQ

Can you provide the ChartMill fundamental rating for CERUS CORP?

ChartMill assigns a fundamental rating of 3 / 10 to CERS.


Can you provide the valuation status for CERUS CORP?

ChartMill assigns a valuation rating of 2 / 10 to CERUS CORP (CERS). This can be considered as Overvalued.


How profitable is CERUS CORP (CERS) stock?

CERUS CORP (CERS) has a profitability rating of 2 / 10.


What is the financial health of CERUS CORP (CERS) stock?

The financial health rating of CERUS CORP (CERS) is 2 / 10.


Can you provide the expected EPS growth for CERS stock?

The Earnings per Share (EPS) of CERUS CORP (CERS) is expected to grow by 25.82% in the next year.